SCHEMBL613700

SCHEMBL613700

CC1CC(=O)C=CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8535407 1.00
SCHEMBL8532549 1.00
SCHEMBL16454361 0.77
SCHEMBL7383676 0.75
SCHEMBL28860808 0.73
SCHEMBL2990170 0.71 NFKB1 (0.32)
SCHEMBL15496326 0.71
SCHEMBL8531191 0.71 TNKS (0.33)
SCHEMBL14498908 0.71 NFKB1 (0.32)
SCHEMBL13266229 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5767295-A REACTING ALDEHYDE WITH SILANOL-SUBSTITUTED BUTADIENE IN THE PRESENCE OF A LEWIS ACID KANEKA CORPORATION (JP) 1998-06-16 US claimed
JP-9077760-A None JP disclosed
US-20250270209-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. 2025-08-28 US disclosed
EP-4522615-A1 LRRK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-19 EP disclosed
EP-4522616-A1 LRRK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-19 EP disclosed
US-20250066356-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2023220238-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
WO-2023220247-A1 LRRK2 INHIBITORS INTERLINE THERAPEUTICS, INC. (US) 2023-11-16 WO disclosed
CN-114716381-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-07-08 CN disclosed
CN-114634447-A Compounds useful as kinase inhibitors 洛克索肿瘤学股份有限公司 2022-06-17 CN disclosed
US-7491494-B2 Evolving new molecular function PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-02-17 US disclosed
WO-2008106139-A1 INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-09-04 WO disclosed
US-7390803-B2 Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity MERCK & CO., INC. (US) 2008-06-24 US disclosed
US-7390803-B2 Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity MERCK & CO., INC. (US) 2008-06-24 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
WO-2007025307-A2 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-03-01 WO disclosed
US-5767295-A REACTING ALDEHYDE WITH SILANOL-SUBSTITUTED BUTADIENE IN THE PRESENCE OF A LEWIS ACID KANEKA CORPORATION (JP) 1998-06-16 US disclosed
JP-H0977760-A PRODUCTION OF 2-SUBSTITUTED OPTICALLY ACTIVE 2,3-DIHYDRO-4H-PYRAN-4-ONE KANEGAFUCHI CHEM IND CO LTD 1997-03-25 JP disclosed
JP-H00977760-A 0001-01-01 JP disclosed